Cortexyme (CRTX) Issues Pipeline Update and Anticipated 2022 Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones
February 1, 2022 8:01 AM ESTNext generation lysine gingipain inhibitor COR588 with novel structure and improved pharmacologic and safety profile prioritized for Alzheimers development
Additional pipeline includes therapeutics in development for coronavirus infection, periodontal disease, and prevention of oral squamous cell carcinoma
Preliminary, unaudited 2021 year-end cash, cash equivalents, and investments of $126.7 million allows for strategic flexibility
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today... More
